Community-acquired PneumoniaNCT03795662
Surviving Pneumonia
An observational study of Community-acquired Pneumonia, run by Nordsjaellands Hospital at 1 site in Denmark.
Trial summary
The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Community-acquired Pneumonia
- How many people
- 2,500 participants
- Where
- 1 siteDenmark
- Study dates
- 7 Jan 2019to 31 Dec 2038
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults (≥18 years) admitted with community-acquired pneumonia
Who may be able to join
- Infiltrate on chest radiograph plus one or more of the following:
- Fever (temperature, ≥38.0°C)
- Hypothermia (<35.0°C),
- New cough with or without sputum production
- Pleuritic chest pain
- Dyspnea
- Altered breath sounds on auscultation.
Who cannot join
- Patients unable to give informed consent
- Patients unwilling to give informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital
Hillerød, 3400
Birgitte Lindegaard, MD, PhD, birgitte.lindegaard.madsen@regionh.dk
About this study
The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.
- Conditions
- Community-acquired Pneumonia
- Being tested
- No intervention
- Keywords
- Community-acquired pneumonia, Diabetes, Immune status, Nutritional status, Physical inactivity, Risk factors
- Medical subject headings
- Community-Acquired Pneumonia, Diabetes Mellitus, Sedentary Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
Obervational
| Study group | Role | What they receive |
|---|---|---|
| Community-acquired pneumonia | Adults over 18 years old admitted with confirmed community-acquired pneumonia. Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of death from any causes
Assessed through patient files
Measured: From date of admission until the day of death from any causes, up to 24 months
Number of participants who develop diabetes
Assessed through patient files and the national registers
Measured: Up to 24 months
Secondary outcomes (3)
Length of hospital stay
Through patient files
Measured: Participants will be followed for the duration of hospital stay, an expected average of 5 days
Oral glucose tolerance test
Measured: Day 1, discharge (an average of 5 days), 1 month and 6-month
Number of participants who are readmitted
Through patient files
Measured: Up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2019
- Study start7 Jan 2019
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Community-acquired PneumoniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nordsjaellands Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Birgitte Lindegaard Madsen, Nordsjaellands Hospital
- Investigators
- Birgitte Lindegaard, Assoc. Prof, Principal investigator, Nordsjaellands Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03795662
- Sponsor's protocol ID
- Surviving Pneumonia
- Status last verified
- Apr 2021
- First submitted
- 9 Nov 2018
- Last updated
- 29 Apr 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ryrso CK, Hegelund MH, Faurholt-Jepsen D, Dungu AM, Ritz C, Olsen MF, Krogh-Madsen R, Lindegaard B. Health-related quality of life in community-acquired pneumonia: a prospective cohort study. Sci Rep. 2026 Jun 23. doi: 10.1038/s41598-026-59119-0. Online ahead of print.
PubMed 42332204Dungu AM, Lundgaard AT, Ryrso CK, Hegelund MH, Jensen AV, Kristensen PL, Krogh-Madsen R, Faurholt-Jepsen D, Ostrowski SR, Banasik K, Lindegaard B. Inflammatory and endothelial host responses in community-acquired pneumonia: exploring the relationships with HbA1c, admission plasma glucose, and glycaemic gap-a cross-sectional study. Front Immunol. 2024 May 22;15:1372300. doi: 10.3389/fimmu.2024.1372300. eCollection 2024.
PubMed 38840922Ryrso CK, Hegelund MH, Dungu AM, Faurholt-Jepsen D, Pedersen BK, Ritz C, Krogh-Madsen R, Lindegaard B. Association between Barthel Index, Grip Strength, and Physical Activity Level at Admission and Prognosis in Community-Acquired Pneumonia: A Prospective Cohort Study. J Clin Med. 2022 Oct 27;11(21):6326. doi: 10.3390/jcm11216326.
PubMed 36362554
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surviving Pneumonia
- ClinicalTrials.gov ID
- NCT03795662
- Acronym / sponsor ID
- Surviving Pneumonia
- Conditions
- Community-acquired Pneumonia
- Keywords
- Community-acquired pneumonia, Diabetes, Immune status, Nutritional status, Physical inactivity, Risk factors
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,500 participants (estimated)
- Lead sponsor
- Nordsjaellands HospitalUniversity, hospital or other
- Study start
- 7 Jan 2019 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2038 (estimated)
- First posted
- 8 Jan 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Community-acquired pneumonia | – | Other: No interventionAdults over 18 years old admitted with confirmed community-acquired pneumonia. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults (≥18 years) admitted with community-acquired pneumonia
Key inclusion criteria (7 listed)
- Infiltrate on chest radiograph plus one or more of the following:
Key exclusion criteria (2 listed)
- Patients unable to give informed consent
- Patients unwilling to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionObervational | Other | Community-acquired pneumonia |
Primary outcome
Number of death from any causes
Time frame: From date of admission until the day of death from any causes, up to 24 months
Assessed through patient files
Number of participants who develop diabetes
Time frame: Up to 24 months
Assessed through patient files and the national registers
3 secondary outcomes
Length of hospital stay
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
Oral glucose tolerance test
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6-month
Number of participants who are readmitted
Time frame: Up to 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2021.
- Derived from this study: PubMed 42332204Ryrso CK, Hegelund MH, Faurholt-Jepsen D, Dungu AM, Ritz C, Olsen MF, Krogh-Madsen R, Lindegaard B. Health-related quality of life in community-acquired pneumonia: a prospective cohort study. Sci Rep. 2026 Jun 23. doi: 10.1038/s41598-026-59119-0. Online ahead of print.
- Derived from this study: PubMed 38840922Dungu AM, Lundgaard AT, Ryrso CK, Hegelund MH, Jensen AV, Kristensen PL, Krogh-Madsen R, Faurholt-Jepsen D, Ostrowski SR, Banasik K, Lindegaard B. Inflammatory and endothelial host responses in community-acquired pneumonia: exploring the relationships with HbA1c, admission plasma glucose, and glycaemic gap-a cross-sectional study. Front Immunol. 2024 May 22;15:1372300. doi: 10.3389/fimmu.2024.1372300. eCollection 2024.
- Derived from this study: PubMed 36362554Ryrso CK, Hegelund MH, Dungu AM, Faurholt-Jepsen D, Pedersen BK, Ritz C, Krogh-Madsen R, Lindegaard B. Association between Barthel Index, Grip Strength, and Physical Activity Level at Admission and Prognosis in Community-Acquired Pneumonia: A Prospective Cohort Study. J Clin Med. 2022 Oct 27;11(21):6326. doi: 10.3390/jcm11216326.
- Individual participant dataSharing planned: No
Related trials for Community-acquired Pneumonia
Active, not recruitingObservational study
A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
Community-Acquired Pneumonia (CAP)
Not yet recruiting
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
Bronchitis, Acute, Community-acquired Pneumonia
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
RecruitingPhase 3
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
Sepsis
Recruiting
Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics
Community-acquired Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Birgitte Lindegaard, Assoc. Prof principal investigator
Nordsjaellands Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Community-acquired Pneumonia, run by Nordsjaellands Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Camilla Ryrsø, MSc (+4548293250, camilla.koch.ryrsoe.01@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of death from any causes (time frame: From date of admission until the day of death from any causes, up to 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03795662, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2021.